|Potent dual inhibitors of TORC1 and TORC2 complexes (KU-0063794 and KU-0068650) demonstrate in vitro and ex vivo anti-keloid scar activity.|
|Jump to Full Text|
|PMID: 23303455 Owner: NLM Status: MEDLINE|
|Mammalian target of rapamycin (mTOR) is essential in controlling several cellular functions. This pathway is dysregulated in keloid disease (KD). KD is a common fibroproliferative dermal lesion with an ill-defined treatment strategy. KD demonstrates excessive matrix deposition, angiogenesis, and inflammatory cell infiltration. In KD, both total and phosphorylated forms of mTOR and p70(S6K)(Thr421/Ser424) are upregulated. Therefore, the aim of this study was to investigate adenosine triphosphate-competitive inhibitors of mTOR kinase previously unreported in keloid and their comparative efficacy with Rapamycin. Here, we present two mTOR kinase inhibitors, KU-0063794 and KU-0068650, that target both mTORC1 and mTORC2 signaling. Treatment with either KU-0063794 or KU-0068650 resulted in complete suppression of Akt, mTORC1, and mTORC2, and inhibition of keloid cell spreading, proliferation, migration, and invasive properties at a very low concentration (2.5 μmol l(-1)). Both KU-0063794 and KU-0068650 significantly (P<0.05) inhibited cell cycle regulation and HIF1-α expression compared with that achieved with Rapamycin alone. In addition, both compounds induced shrinkage and growth arrest in KD, associated with the inhibition of angiogenesis, induction of apoptosis, and reduction in keloid phenotype-associated markers. In contrast, Rapamycin induced minimal antitumor activity. In conclusion, potent dual mTORC1 and mTORC2 inhibitors display therapeutic potential for the treatment of KD.|
|Farhatullah Syed; Hitesh J Sanganee; Ashwani Bahl; Ardeshir Bayat|
Related Documents :
|15979845 - Cooperation of h2o2-mediated erk activation with smad pathway in tgf-beta1 induction of...
17017565 - Triggering endogenous neuroprotective mechanisms in parkinson's disease: studies with a...
24273605 - Type ii cgmp-dependent protein kinase inhibits epidermal growth factor-induced phosphat...
20806405 - Phosphorylation of erk in the spinal dorsal horn following pancreatic pronociceptive st...
23765875 - Stimulation of somatic cell reprogramming by eras-akt-foxo1 signaling axis.
2549385 - Phosphorylation of 2',3'-dideoxyinosine by cytosolic 5'-nucleotidase of human lymphoid ...
|Type: Comparative Study; In Vitro; Journal Article; Research Support, Non-U.S. Gov't Date: 2013-01-10|
|Title: The Journal of investigative dermatology Volume: 133 ISSN: 1523-1747 ISO Abbreviation: J. Invest. Dermatol. Publication Date: 2013 May|
|Created Date: 2013-04-18 Completed Date: 2013-07-09 Revised Date: 2013-09-30|
Medline Journal Info:
|Nlm Unique ID: 0426720 Medline TA: J Invest Dermatol Country: United States|
|Languages: eng Pagination: 1340-50 Citation Subset: IM|
|Plastic & Reconstructive Surgery Research, Manchester Institute of Biotechnology, University of Manchester, Manchester, UK.|
|APA/MLA Format Download EndNote Download BibTex|
Cell Movement / drug effects
Cell Proliferation / drug effects
Dose-Response Relationship, Drug
Enzyme Inhibitors / pharmacology, therapeutic use*
Hypoxia-Inducible Factor 1, alpha Subunit / metabolism
Immunosuppressive Agents / pharmacology, therapeutic use
Keloid / drug therapy*, metabolism, pathology*
Morpholines / pharmacology, therapeutic use*
Multiprotein Complexes / antagonists & inhibitors*, drug effects, metabolism
Phosphatidylinositol 3-Kinases / metabolism
Proto-Oncogene Proteins c-akt / metabolism
Pyrimidines / pharmacology, therapeutic use*
Signal Transduction / drug effects
Sirolimus / pharmacology, therapeutic use
TOR Serine-Threonine Kinases / antagonists & inhibitors*, drug effects, metabolism
|0/Enzyme Inhibitors; 0/HIF1A protein, human; 0/Hypoxia-Inducible Factor 1, alpha Subunit; 0/Immunosuppressive Agents; 0/KU-0068650; 0/Ku 0063794; 0/Morpholines; 0/Multiprotein Complexes; 0/Pyrimidines; 0/TOR complex 2; 0/mechanistic target of rapamycin complex 1; 53123-88-9/Sirolimus; EC 2.7.1.-/Phosphatidylinositol 3-Kinases; EC 220.127.116.11/TOR Serine-Threonine Kinases; EC 18.104.22.168/Proto-Oncogene Proteins c-akt|
Journal ID (nlm-ta): J Invest Dermatol
Journal ID (iso-abbrev): J. Invest. Dermatol
Publisher: Nature Publishing Group
Copyright © 2013 The Society for Investigative Dermatology, Inc
Received Day: 22 Month: 07 Year: 2012
Revision Received Day: 29 Month: 10 Year: 2012
Accepted Day: 02 Month: 11 Year: 2012
Print publication date: Month: 05 Year: 2013
Electronic publication date: Day: 10 Month: 01 Year: 2013
Volume: 133 Issue: 5
First Page: 1340 Last Page: 1350
PubMed Id: 23303455
Publisher Item Identifier: jid2012483
|Potent Dual Inhibitors of TORC1 and TORC2 Complexes (KU-0063794 and KU-0068650) Demonstrate In Vitro and Ex Vivo Anti-Keloid Scar Activity Alternate Title:Inhibition of TORC1 and TORC2 Complexes in Keloid|
|Hitesh J Sanganee3|
1Plastic & Reconstructive Surgery Research, Manchester Institute of Biotechnology, University of Manchester, Manchester, UK
2Faculty of Medical and Human Sciences, Manchester Academic Health Science Centre, University Hospital of South Manchester NHS Foundation Trust, Institute of Inflammation and Repair, University of Manchester, Manchester, UK
3New Opportunities iMed, AstraZeneca R&D Alderley Park, Macclesfield, Cheshire, UK
4Manchester Academic Health Science Centre, University of Manchester, Manchester, UK
|*Plastic & Reconstructive Surgery Research, Manchester Institute of Biotechnology, University of Manchester, 131 Princess Street, Manchester M1 7DN, UK. E-mail: Ardeshir.Bayat@manchester.ac.uk
The mammalian target of Rapamycin (mTOR) is a 289-kDa serine–threonine kinase that regulates cellular activity (Dazert and Hall, 2011). mTOR kinases form two distinct multiprotein complexes mTORC1 and mTORC2. Inhibition of mTORC1 alone by rapalogs leads to enhanced activation of PI3K axis by the mTOR-S6K-IRS1-negative feedback loop (Bracho-Valdes et al., 2011). mTORC2 phosphorylates Akt on Ser473, increasing its enzyme activity up to 10-fold (Chresta et al., 2010). Activated Akt regulates many cellular functions. Thus, mTORC2 is an attractive target in cancer (Sini et al., 2010; Sparks and Guertin, 2010).
Keloid disease (KD) is a fibroproliferative lesion characterized by excessive deposition of extracellular matrix (ECM) such as collagen (Shih et al., 2010), fibronectin (FN), and α-smooth muscle actin (α-SMA) (Supplementary Figure S1a online) (Ong et al., 2007). KD fibroblasts possess cancer-like properties (Vincent et al., 2007), with overexpression of cytokines and increased angiogenesis (Shih et al., 2010) (Supplementary Figure S1b online). KD infiltrates the surrounding tissue with up to 80% recurrence post excision (Mall et al., 2002). Many treatment modalities exist, but they fail to prevent KD recurrence (Patel and Lawrence Cervino, 2010), hence the urgency for effective treatment options. mTOR is a regulator of collagen expression in dermal fibroblasts shown by the inhibition of ECM deposition with Rapamycin (Shegogue and Trojanowska, 2004). The PI3K/Akt/mTOR pathway leads to the overproduction of ECM in KD, and targeting of the mTOR pathway is a potential therapeutic approach in eradicating keloids (Lim et al., 2003; Zhang et al., 2006; Ong et al., 2007). We hypothesized that dual mTORC1 and mTORC2 inhibition provides superior inhibition of Akt signaling and anti-angiogenic activity. Unlike Rapamycin, which inhibits mTORC1 alone (Benjamin et al., 2011), here we demonstrate that both KU-0063794 and KU-0068650 (referred to collectively as AstraZeneca (AZ) compounds) are highly selective adenosine triphosphate-competitive inhibitors (Garcia-Martinez et al., 2009) of mTOR kinase activity, with no toxicity in vivo (Malagu et al., 2009; Janes et al., 2010; Dormond-Meuwly et al., 2011), similar in mechanism of action to AZD8055 (Chresta et al., 2010; Sini et al., 2010).
Therefore, we investigated (i) the baseline cellular levels of mTOR, p70S6K, and their activated forms between KD and extra-lesional tissue (ELT) obtained from the same patient, (ii) the effect of both AZ compounds on KD growth and ECM deposition in vitro and ex vivo, and (iii) differences between KU-0063794 and KU-0068650 to a well-recognized mTOR inhibitor Rapamycin.
There was a differential expression of mTOR and p70S6K and their phosphorylated forms in KD compared with ELT and extra-lesional fibroblasts (ELFs) (Supplementary Figure S1c online). Total and phosphorylated forms of mTOR showed high expression of both forms in KD compared with ELT (Figure 1a). The average total immunoreactivity using In-Cell Western Blotting showed a significant (*P<0.02) increase in mTOR, p-mTOR, p70S6K, and phospho-p70S6K(Thr421/Ser424) in keloid fibroblasts (KFs) compared with ELFs (Figure 1b and c). Thus, mTOR is active in KD.
The inhibitory potential of both AZ compounds was compared with Rapamycin, an allosteric mTORC1 inhibitor (Benjamin et al., 2011), in intracellular PI3K/Akt/mTOR signaling of KFs and ELFs. Both AZ compounds demonstrated a dose-dependent, significant (P<0.01) decrease in pAkt-S473. mTORC1 downstream substrates, 4E-BP1, and S6 ribosomal protein were efficiently (P<0.01) dephosphorylated. Both AZ compounds neither inhibited phosphorylated mitogen-activated protein kinase nor pAkt-T308 at a low concentration (2.5 μmol l−1). Furthermore, both AZ compounds reduced (P<0.05) phosphorylation of GSK3β, a critical downstream element of the PI3kinase/Akt and HIF1-α (P<0.01). Rapamycin (20 μmol l−1) significantly reduced pAkt-T308, but had no effect on pAkt-S473 (Figure 1d). Both AZ compounds did not cause inhibition of PI3K/Akt/mTOR signaling in ELFs at 2.5 μmol l−1 (Supplementary Figure S2 online). This discrepancy could be due to reduced expression of mTOR and p-mTOR in ELFs compared with KFs. Therefore, both AZ compounds appear specific in the inhibition of pAkt-S473.
Both AZ compounds showed a significant (P⩽0.01) reduction of p-mTOR, Rictor, and Raptor immunoreactivity (Figure 1e). In contrast, Rapamycin only reduced p-mTOR and Raptor immunoreactivity (P<0.05). To confirm the effect on the mTORC1 and mTORC2 complex observed in KFs, we performed an immunoprecipitation assay. Predictably, both AZ compounds inhibited the association of mTORC1 with Raptor and mTORC2 with Rictor, whereas Rapamycin failed to show mTORC2 inhibition in KFs (Figure 1f). These results demonstrate that both AZ compounds inhibit mTORC1 and mTORC2 inhibitors as described previously with AZD8055 (Chresta et al., 2010) and P529 (Xue et al., 2008).
The effect of KU-0063794 and KU-0068650 on cell behavior was compared with Rapamycin with the water-soluble tetrazolium salt-1 (WST-1) assay using a range of concentrations. Treatment with different concentrations resulted in significant (P⩽0.03) reduction in cell viability/metabolic activity in a dose-dependent manner. However, both AZ compounds had a significantly (P<0.03) higher effect on KFs compared with ELFs. In contrast, Rapamycin showed a similar effect on KFs and ELFs. After compound removal, the effect of Rapamycin recovered in both KFs (Figure 2a) and ELFs (Figure 2b) compared with both AZ compounds.
The cell growth inhibition displayed by both AZ compounds was evaluated using a label-free real-time cell analysis (RTCA) on a microelectronic sensor array (Syed et al., 2012a, 2012b). Both AZ compounds (P<0.02) and Rapamycin significantly (P<0.05) inhibited cell spreading, attachment, and proliferation in a time- and dose-dependent manner in KFs. Similar dose-dependent and time-dependent inhibitions were also seen in ELFs. In addition, both AZ compounds had a sustained effect on KFs and ELFs seen by the recovery of cells after removal of the inhibitors at 24 hours. When treatment with all three compounds was complete, KFs and ELFs were not able to recover within 26–30 hours compared with the vehicle-treated group. Importantly, in the KU-0068650-treated group, the average cell index was reduced further, suggesting that the effect was sustained in this group. However, in the KU-0063794- and Rapamycin-treated groups, there was an increase in the average cell index in KFs (Figure 2c and Supplementary Figure S3a online) compared with ELFs (Supplementary Figure S3b and c online). Compared with Rapamycin (20 μmol l−1), KU-0063794 and KU-0068650 were highly effective even at a very low concentration (2.5 μmol l−1). Taken together, both AZ compounds significantly (P<0.05) decreased KF and ELF proliferation in a concentration- and time-dependent manner.
Cell growth inhibition properties of both AZ compounds were evaluated using an in vitro collagen-coated two-dimensional migration assay. Treatment with both AZ compounds significantly (P<0.01) reduced the migration of KFs compared with the Rapamycin-treated group, in a concentration-dependent manner. Rapamycin also reduced the migration of KFs significantly (P<0.05), but at a higher concentration (20 μmol l−1) compared with the vehicle control. However, migration inhibitory effect by both AZ compounds was low in ELFs compared with KFs (Figure 3a and b).
An Oris three-dimensional basement membrane extract invasion and detection assay was used to assess the anti-invasive properties of both AZ compounds. KFs showed a high level of invasion (P<0.01) compared with ELFs. Treatment with both AZ compounds significantly (P<0.01) reduced the invasive properties of KFs at 48 hours post treatment, whereas Rapamycin showed significant (P<0.05) inhibition of KF invasion with a low efficacy compared with both AZ compounds (Figure 3c and d). These results suggest that both AZ inhibitors have potential anti-invasive properties.
On the basis of the WST-1 and RTCA results, it was hypothesized that both AZ compounds may achieve their inhibitory effect via apoptosis or cellular necrosis. Indeed, both compounds induced significant apoptosis, as there was an increase in Annexin V–positive cells (P<0.05) at 24 hours post treatment, compared with Rapamycin (5 μmol l−1) and control group, in a concentration-dependent manner. However, higher doses (20 μmol l−1) of Rapamycin also caused significant (P<0.05) apoptosis. Importantly, both AZ compounds caused a reduced level of apoptosis in ELFs compared with KFs (Supplementary Figure S4a and b online). Thus, both AZ compounds inhibited cellular activity by inducing apoptosis.
Both KU-0063794 and KU-0068650 significantly (P⩽0.01) downregulated the expression of collagen, FN, and α-SMA compared with Rapamycin (P⩽0.05) in a concentration-dependent manner at messenger RNA in KFs (Figure 4a) and protein levels in both KFs (Figure 4b and Supplementary Figure S5a–c online) and ELFs (Supplementary Figure S5a–d online). However, both AZ compounds inhibited ECM-related proteins in ELFs, at higher concentrations compared with KFs.
RTCA and WST-1 analyses demonstrated reduced levels of cell proliferation and viability/metabolic activity. The expression levels of cell cycle proteins proliferating cell nuclear antigen and Cyclin D were significant. Concentration-dependent downregulation was observed in fibroblasts treated with both AZ compounds at protein levels. However, Rapamycin showed a significant (P<0.05) reduction in proliferating cell nuclear antigen and Cyclin D expression at a higher concentration compared with vehicle control (DMSO) in KFs and ELFs. Both AZ compounds had a minimal effect on cell cycle proteins at 2.5 μmol l−1 in ELFs (Figure 4b and Supplementary Figure S5d online).
To evaluate the therapeutic potential of both AZ compounds in KD, we used an ex vivo keloid organ culture (OC) model (Bagabir et al., 2012) as described previously. Both AZ compounds (10 μmol l−1) significantly (P⩽0.02) induced the shrinkage and reduced the keloid OC volume compared with the vehicle group on day 3. However, Rapamycin treatment (20 μmol l−1) also significantly (P<0.05) decreased the average weight of the keloid OC at week 1 compared with the vehicle group (Figure 4c and Supplementary Figure S6a online).
Both AZ compounds (2.5 μmol l−1) and Rapamycin significantly (P<0.05) reduced metabolic activity from day 3 to week 4 as compared with the vehicle group evidenced by an MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay (Figure 4d). Furthermore, both AZ compounds significantly (P<0.02) increased apoptosis on day 3 in situ compared with the Rapamycin-treated group. However, Rapamycin did not cause any significant apoptosis until week 1 post treatment, compared with the vehicle group. At week 4, 55–65% TUNEL-positive cells were observed in both the AZ inhibitor (10 μmol l−1)–treated groups, whereas the Rapamycin (20 μmol l−1)-treated group showed only 35–40% TUNEL-positive cells (Figure 5a and b). Thus, both AZ compounds caused shrinkage of keloid tissue in an ex vivo model on day 3 post treatment, plus they reduced metabolic activity and induced massive apoptosis at 2.5 μmol l−1 compared with Rapamycin (20 μmol l−1) in a keloid ex vivo model.
In hematoxylin and eosin–stained tissue sections, histological changes were evaluated in the epidermis, papillary dermis, and reticular dermis. Up to day 3, the overall tissue architecture was well preserved in the Rapamycin-treated group, whereas at week 1 both AZ compound–treated groups showed reduced cellularity and thinning of the stratum granulosum and papillary dermis. Both KU-0063794- and KU-0068650-treated groups showed that the epidermis was completely detached from week 1 to week 4 of treatment and exhibited more intense tissue damage, characterized by keloid cell loss, increased number of cells with pyknotic nuclei, and reduced fibrosis (thick collagen bundles). In contrast, Rapamycin showed minimal effect on keloid OC despite a higher concentration (20 μmol l−1). However, at week 4, Rapamycin-treated explants showed detachment of the epidermis, with increased number of cells showing pyknotic nuclei, although the overall structure was better preserved compared with AZ compound–treated keloid tissue. Both AZ compounds also induced a noticeable decrease in the hyalinized collagen bundles in the keloid tissue model at week 1 through to week 4 (Supplementary Figure S6b online).
Keloid tissue shows increased blood vessel density compared with extra-lesional skin (Supplementary Figure S1b online). Therefore, we examined the anti-angiogenic and anti-vascular properties of both AZ compounds. Indeed, these showed a drastic reduction in the number of CD31+ve (endothelial cell marker) (Figure 5c) and CD34+ve (a microvascular endothelial cell marker) cells (Figure 5d) in the papillary and reticular dermis at week 1 up to week 4. In contrast, Rapamycin showed a noticeable reduction in both anti-CD31 and anti-CD34 expression only at week 4. The above findings suggest that significant shrinkage of keloid tissue in both AZ compound–treated groups may be due to a combination of anti-proliferative and apoptotic effects along with a compound-related anti-angiogenic and anti-vascular effect.
To evaluate the ex vivo effects of both AZ compounds compared with Rapamycin, on intracellular signaling in situ, tissue was analyzed with immunohistochemistry post treatment. In both KU-0063794- and KU-0068650-treated groups, the expression of pAkt-S473 (Supplementary Figure S7a online), p-mTOR (Supplementary Figure S7b online), and pS6 (Supplementary Figure S7c online) was reduced at week 1 compared with the Rapamycin-treated group, whereas in the Rapamycin-treated group pAkt-S473, p-mTOR, and pS6 reduced at week 4.
Finally, we elucidated the potential anti-fibrotic effect of both KU-0063794 and KU-0068650 in keloid OC in situ. As expected, treatment with both AZ inhibitors reduced the immunoreactivity of pro-collagen I at week 1 post treatment compared with the Rapamycin-treated group (Supplementary Figure S8 online). Similarly, FN was reduced by both AZ compounds on day 3 and week 1 compared with the Rapamycin-treated group (Supplementary Figure S9a online). We also assessed for the expression of α-SMA, which showed a significant reduction by both the AZ compounds at week 1 up to week 4 (Supplementary Figure S9b online). Nevertheless, Rapamycin also suppressed the expression level of pro-collagen, FN, and α-SMA at week 1 up to week 4 at a higher concentration compared with the vehicle group. In summary, both AZ compounds caused a significant reduction of ECM-related proteins in keloid tissue compared with Rapamycin.
Using in vitro and ex vivo experiments, here we demonstrate two compounds, previously unreported in keloid, KU-0063794 and KU-0068650, that show promising anti-fibrotic activity. Both compounds are not only potent but also selective mTORC1 and mTORC2 inhibitors compared with Rapamycin.
Both AZ compounds attenuated Akt phosphorylation at specific Ser473 and significantly inhibited mTORC1 and mTORC2 complexes, whereas Rapamycin only inhibited the mTORC1 complex. Consistent with our results, recently, KU-0063794 (Garcia-Martinez et al., 2009), AZD8055 (Chresta et al., 2010; Marshall et al., 2011), Palomid 529 (Xue et al., 2008), NVP-BEZ235 (Chapuis et al., 2010; Santiskulvong et al., 2011), and WYE-125132 (Yu et al., 2010) have shown similar inhibitory effect on mTORC1 and mTORC2. These results demonstrate that these AZ compounds have a potential anti-fibrotic effect. Both AZ compounds showed more effective inhibition of KF cell attachment, spreading, proliferation, and caused cytotoxicity and reduced viability/metabolic activity, as well as inhibited migration and invasion properties at a low concentration (2.5 μmol l−1) compared with Rapamycin (20 μmol l−1).
The cell inhibition properties were achieved partly by suppressing proliferating cell nuclear antigen and cyclin D. Reorganization of the actin cytoskeleton is a multistep process and is an early event in cellular activity (Bracho-Valdes et al., 2011). Both AZ compounds are potent inhibitors of mTORC2 (Jacinto et al., 2004; Bracho-Valdes et al., 2011), and this may explain the inhibition of keloid cell attachment, spreading, migration, and invasion. In the initial in vitro experiments, using lactate dehydrogenase (cytotoxicity) assay, both AZ compounds showed toxicity in keloid and ELFs. However, the efficacy of both compounds was reduced in ELFs. Importantly, the effect of both compounds was reversible within 24 hours of drug removal in extra-lesional primary fibroblasts but not in KFs (data not shown). From these results, both AZ compounds are highly selective in inhibiting KF activity.
Activation of the PI3K/Akt/mTOR pathway is important for cell growth (Morgensztern and McLeod, 2005). As the inhibition of PI3K/Akt/mTOR is known to induce apoptosis, both AZ compounds showed severe apoptosis. In contrast, Rapamycin displayed minimal apoptosis. The enhanced ability of both AZ inhibitors to induce apoptosis may explain why both compounds showed higher activity against KF inhibition.
There is increasing evidence that the PI3K/Akt/mTOR network has an important role in ECM regulation in fibrosis (Ong et al., 2007; Dazert and Hall, 2011). Collagen, FN, and α-SMA are proteins characteristic of the keloid phenotype (Ong et al., 2007; Shih et al., 2010). Overall, these proteins were selected to assess the effects on ECM production in response to both AZ compounds in KD. Both KU-0063794 and KU-0068650 reduced collagen I, FN, and α-SMA expression in vitro more significantly compared with Rapamycin.
We further explored the antitumour activity of both KU-0063794 and KU-0068650 in an ex vivo model (Bagabir et al., 2012). Treating the keloid OC with both inhibitors demonstrated histologically reduced cellularity, inflammation, reduced hyalinized collagen bundles, and reduced the average keloid volume in a shrinkage assay. The effect of both compounds on PI3K/Akt/mTOR signaling and angiogenesis showed a significant reduction in p-mTOR and pAkt-S473 levels and significant anti-angiogenic properties. Analysis of the effect of both KU-0063794 and KU-0068650 on keloid-associated fibrotic markers showed strong inhibition of collagen I, FN, and α-SMA compared with Rapamycin, at low concentrations in an ex vivo model.
KU-0063794 is a potent and highly specific mTOR inhibitor for both mTORC1 and mTORC2, with an IC50 of 10 nℳ, but it does not suppress the activity of 76 other protein kinases or seven lipid kinases, including Class 1 PI3Ks at 1,000-fold higher concentrations (Garcia-Martinez et al., 2009). In addition, there is no literature available on the efficacy of KU-0068650, which is similar in structure to both KU-0063794 and AZD8055. Moreover, the active form of mTOR (phospho-mTOR) is overexpressed in KD but not in normal skin (Ong et al., 2007; Syed et al., 2012a).
Overall, both AZ compounds show significant inhibition of primary KFs at very low concentrations. Indeed, a significant effect by both AZ compounds was only seen in primary normal skin fibroblasts at much higher concentrations, which could have resulted in nonspecific effects on these cells. Thus, the specificity of both AZ compounds is hitherto implied, as both seem to act selectively on cells with active levels of mTOR signaling.
Clinically adverse events have been demonstrated with the use of mTORC1 inhibitor, Sirolimus, and its analogs (Xue et al., 2008; Lewis et al., 2009; Jorge and David, 2011). However, AZD8055 (a similar compound structurally to both the AZ compounds used in this study) significantly reduced the clonogenic growth of leukemic progenitors from primary CD34+Ve AML cells ex vivo. In contrast, exposure to AZD8055 barely affected the clonogenic growth of normal CD34+Ve hematopoietic progenitors even at maximal concentrations (Willems et al., 2012). As both AZ compounds are from a similar family of compounds to AZD8055, it is therefore plausible that both of these compounds may not be toxic to normal cells. However, this assertion remains to be formally tested in both of these AZ compounds. Importantly, it remains to be determined whether these compounds have a real measurable clinical effect on disease tissue in an in vivo scenario before their safe potential use in keloid patients.
Here, we propose a model for the mechanism of action of these compounds on KD (Supplementary Figure S10 online). The PI3K/Akt/mTOR axis is an important target in keloid pathogenesis, as dual inhibition of mTOR kinases by both the AZ compounds inhibits cell proliferation, migration, and invasion, and causes severe apoptosis compared with an allosteric mTORC1 inhibitor. Thus, both KU-0063794 and KU-0068650 dual mTORC1 and mTORC2 inhibitors may prove to be innovative therapeutic candidates for the treatment of keloid. Interestingly, both compounds showed higher efficacy in keloid compared with non-keloid derived cells. This could be due to active PI3K/Akt/mTOR axis in KF compared with ELFs, suggesting that both compounds are highly selective for PI3K/Akt/mTOR. Another important observation was that KU-0068650 showed a greater efficacy when compared with KU-0063794 at a similar concentration (2.5 μmol l−1) in every assay, possibly because of higher solubility, the presence of methyl groups, and lower IC50 of KU-0068650 (Supplementary Table S2 online).
This study was conducted in accordance with the ethical principles of Good Clinical Practice and the Declaration of Helsinki. This study received ethical approval from the local research committee (Manchester, UK), and all subjects gave full written, informed consent. Keloid tissues were harvested at the time of surgery from patients confirmed to have clinical and pathological evidence of KD (Syed et al., 2011; Bagabir et al., 2012) (Supplementary Figure S1c online). Thirty-one keloid samples (out of 31 KD samples, 10 samples were used for ex vivo study) (Supplementary Table S1 online) were ethically consented (ethical approval was obtained from NHS Ethical Committee).
Keloid and ELTs (Supplementary Figure S1c online) (ELT samples were collected away from the keloid and importantly show no lesional involvement in hematoxylin and eosin) were collected in DMEM using a standard protocol to extract fibroblasts (Syed et al., 2011, 2012a; Syed and Bayat, 2012a). In this study, passage 1 (p1) to passage 4 (p4) cells were used.
KU-0063794 and KU-0068650 (AstraZeneca, London, UK) (Supplementary Table S2 online) (2.5; 10; 15; 20 μmol l−1) were compared with Rapamycin (Merck, Middlesex, UK) (5; 20 μmol l−1). Camptothecin (Sigma-Aldrich, Dorset, UK) at a concentration of 250 ng ml−1 was used as positive control for RTCA, lactate dehydrogenase, WST-1, and apoptotic assays.
Fibroblasts were treated with various concentrations of KU-0063794, KU-0068650, and Rapamycin, and In-Cell Western Blotting was performed using an optimized protocol (Syed and Bayat, 2012a; Syed et al., 2012a, 2012b). For all antibodies used, see Supplementary Tables S3 and S4 online.
Primary KFs (2.5 × 105 cells per well) were grown in 24-well plates for 24 hours. Cells were treated with compounds for 16 hours, and then lysed with cell lysis buffer (1 × radioimmunoprecipitation assay buffer, Cell Signaling, Hertfordshire, UK). mTOR (1:75) antibody was added and immune complexes were allowed to form by incubating on a rotor overnight at 4 °C. A ∼50–55% slurry of protein G-Sepharose (Sigma-Aldrich) was added and incubation was carried out for 3 hours at 4 °C. Immunoprecipitates were captured with protein G-Sepharose, washed three times with cell lysis buffer, and analyzed by immunoblotting. Protein concentrations were determined using the bicinchoninic acid protein assay reagent kit (Thermo Scientific, Loughborough, UK). Equal amounts of protein (100 μg per Lane) were separated by NuPAGE Novex Bis-Tris Gels and transferred onto nitrocellulose membranes using iBlot Dry blotting device (Invitrogen, Paisley, UK). Membranes were blocked with blocking buffer (LI-COR, Cambridge, UK) for 30–45 minutes at room temperature. The membranes were incubated with different concentrations of primary antibodies (Supplementary Table S3 online) overnight at 4 °C. After incubation, the membranes were washed and incubated with secondary antibodies (Supplementary Table S4 online) for 1 hour 15 minutes at room temperature. The membranes were washed and the signal was detected using the Odyssey infrared imaging system (LI-COR); β-actin served as loading control.
We used a label-free RTCA on a microelectronic system to measure cell attachment, spreading, and proliferation. The basic principle of the RTCA system and the optimized protocol were described previously in detailed (Xing et al., 2005; Syed and Bayat, 2012a; Syed et al., 2012b).
The assay was performed as described previously (Syed et al., 2012a; Syed and Bayat, 2012b). Briefly, a Oris 96-well plate (Oris migration assay kit, Cambridge Bioscience, Cambridge, UK) was coated with 9 μg ml−1 rat-tail collagen (BD Bioscience, Oxford, UK) and incubated for 30–45 minutes at 37 °C/5% CO2. After incubation, Oris cell seeding stoppers were inserted according to the manufacturer's instructions. Serum-starved KFs and ELFs were pre-labeled with PKH26 (Sigma-Aldrich) according to the manufacturer's instructions. A density of 2.5 × 105 cells per well was seeded in each well of the Oris 96-well migration assay plates. The plate was then incubated overnight at 37 °C/5% CO2. The next day, the cell seeding stoppers were removed and 100 μl of fresh medium was added with or without different compounds as above; the plates were further incubated and the cells were allowed to migrate for ∼30 hours in the migration zone. Micrographs were captured using × 4 magnification of inverted microscopy (Olympus UK, Southend-on-Sea, UK). Cells in the migration zone were counted from four independent experiments and average migrated cells were plotted on the graphs.
Inhibition of the invasive capacity of KU-0063794, KU-0068650, and Rapamycin was tested using basement membrane extract in vitro in three-dimensional invasion assay (Oris Invasion and detection assay kit, Cambridge Bioscience) as described previously (Syed and Bayat, 2012a; Syed et al., 2012a). Briefly, serum-starved cells at a density of 2.5 × 105 cells per well were seeded in Oris invasion assay plates and allowed to attach for 8–12 hours at 37°C/5% CO2; after cell attachment, the stoppers were removed from the wells and cells were washed once with phosphate-buffered saline and 40 μl of basement membrane extract was added to the cells. The plates were incubated (at 37°C, 5% CO2) for 45–60 minutes. Compound treatments were given for 48 hours and cells were allowed to invade in the 2-mm invasion zone created by Oris cell seeding stoppers. The cells were stained with Calcein AM according to the manufacturer's instructions. Micrographs were captured using × 4 magnification of inverted Olympus IX71 (Olympus UK Ltd., Southend-on-Sea, UK) microscopy. Invaded cells in the invasion zone were counted from four independent experiments and average invaded cells were plotted on the graphs.
Please see Supplementary data online for methodology used in this study.
Supplementary material is linked to the online version of the paper at http://www.nature.com/jid
The senior author AB acknowledges the support of AZ in funding this study and for generous support from the GAT family Foundation and the NIHR (UK) in support of his work. Our gratitude goes to the study participants and nursing staff of University Hospital of South Manchester NHS Foundation Trust. We thank Dr Rania A. Bagabir, a member of the Bayat group, for her expertise and support in immunohistochemistry.
|α-SMA||α-smooth muscle actin|
|mTOR||mammalian target of rapamycin|
|RTCA||real-time cell analysis|
|WST-1||water-soluble tetrazolium salt-1|
Dr Hitesh J Sanganee is an employee of AZ and Dr Ashwani Bahl was an employee of AZ at the time of collaboration, but has now moved to work for Eli Lilly Pharmaceuticals. The compounds (KU-0063794 & KU-0068650) were provided by AZ (UK). The Bayat group was approached by AZ to conduct a study into the utility of these compounds in KD and were duly funded to carry out this work. Nevertheless, the senior author, Dr Bayat, and members of his group do not hold any intellectual property or rights to the use or sale of these particular compounds as they remain the sole property of AZ.
|Bagabir R,Syed F,Paus R,et al. Year: 2012Long-term organ culture of keloid disease tissueExp Dermatol2137638122509836|
|Benjamin D,Colombi M,Moroni C,et al. Year: 2011Rapamycin passes the torch: a new generation of mTOR inhibitorsNat Rev Drug Discov1086888022037041|
|Bracho-Valdes I,Moreno-Alvarez P,Valencia-Martienz I,et al. Year: 2011mTORC1-and mTORC2-interacting proteins keep their multifunctional partners focusedIUBMB Life6389691421905202|
|Chapuis N,Tamburini J,Green AS,et al. Year: 2010Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemiaClin Cancer Res165424543520884625|
|Chresta CM,Davies BR,Hickson I,et al. Year: 2010AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activityCancer Res7028829820028854|
|Dazert E,Hall MN. Year: 2011mTOR signaling in diseaseCurr Opin Cell Biol2374475521963299|
|Dormond-Meuwly A,Roulin D,Dufour M,et al. Year: 2011The inhibition of MAPK potentiates the anti-angiogenic efficacy of mTOR inhibitorsBiochem Biophys Res Commun40771471921439267|
|Garcia-Martinez JM,Moran J,Clarke RG,et al. Year: 2009Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)Biochem J421294219402821|
|Jacinto E,Loewith R,Schmidt A,et al. Year: 2004Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitiveNat Cell Biol61122112815467718|
|Janes MR,Limon JJ,So L,et al. Year: 2010Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitorNat Med1620521320072130|
|Jorge LJ,David S. Year: 2011Potential therapeutic roles for inhibition of the PI3K/Akt/mTOR pathway in the pathophysiology of diabetic retinopathyJ Ophthalmol2011.doi:10.1155/2011/589813|
|Lewis GP,Chapin EA,Byun J,et al. Year: 2009Muller cell reactivity and photoreceptor cell death are reduced after experimental retinal detachment using an inhibitor of the Akt/mTOR pathwayInvest Ophthalmol Vis Sci504429443519369237|
|Lim IJ,Phan TT,Tan EK,et al. Year: 2003Synchronous activation of ERK and phosphatidylinositol 3-kinase pathways is required for collagen and extracellular matrix production in keloidsJ Biol Chem278408514085812907681|
|Malagu K,Duggan H,Menear K,et al. Year: 2009The discovery and optimisation of pyrido [2, 3-d] pyrimidine-2, 4-diamines as potent and selective inhibitors of mTOR kinaseBioorg Med Chem Lett195950595319762236|
|Mall JW,Pollmann C,Muller JM,et al. Year: 2002[Keloid of the earlobe after ear piercing. Not only a surgical problem]Chirurg7351451612089838|
|Marshall G,Howard Z,Dry J,et al. Year: 2011Benefits of mTOR kinase targeting in oncology: pre-clinical evidence with AZD8055Biochem Soc Trans3945645921428919|
|Morgensztern D,McLeod HL. Year: 2005PI3K/Akt/mTOR pathway as a target for cancer therapyAnticancer Drugs1679780316096426|
|Ong CT,Khoo YT,Mukhopadhyay A,et al. Year: 2007mTOR as a potential therapeutic target for treatment of keloids and excessive scarsExp Dermatol1639440417437482|
|Patel NP,Lawrence Cervino A. Year: 2010Keloid treatment: is there a role for acellular human dermis (Alloderm)J Plast Reconstr Aesthet Surg631344134819699700|
|Santiskulvong C,Konecny GE,Fekete M,et al. Year: 2011Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinomaClin Cancer Res172373238421372221|
|Shegogue D,Trojanowska M. Year: 2004Mammalian target of rapamycin positively regulates collagen type I production via a phosphatidylinositol 3-kinase-independent pathwayJ Biol Chem279231662317515047702|
|Shih B,Garside E,McGrouther DA,et al. Year: 2010Molecular dissection of abnormal wound healing processes resulting in keloid diseaseWound Repair Regen1813915320002895|
|Sini P,James D,Chresta C,et al. Year: 2010Simultaneous inhibition of mTORC1 and mTORC2 by mTOR kinase inhibitor AZD8055 induces autophagy and cell death in cancer cellsAutophagy655355420364113|
|Sparks CA,Guertin DA. Year: 2010Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapyOncogene293733374420418915|
|Syed F,Ahmadi E,Iqbal SA,et al. Year: 2011Fibroblasts from the growing margin of keloid scars produce higher levels of collagen I and III compared with intralesional and extralesional sites: clinical implications for lesional site-directed therapyBr J Dermatol164839620849516|
|Syed F,Bayat A. Year: 2012aNotch signalling pathway in keloid disease: Enhanced fibroblast activity in a Jagged-1 peptide dependent manner in lesional versus extra-lesional fibroblastsWound Repair Regen2068870622985040|
|Syed F,Bayat A. Year: 2012bSuperior effect of combination versus single steroid therapy in keloid disease: a comparative in vitro analysis of glucocorticoidsWound Repair Regendoi:10.1111/j.1524-475X.2012.00862.x|
|Syed F,Sherris D,Paus R,et al. Year: 2012aKeloid disease can be inhibited by antagonizing excessive mTOR signalling with a novel dual TORC1/2 inhibitorAm J Pathol1811642165822982188|
|Syed F,Thomas A,Singh S,et al. Year: 2012bIn vitro study of novel collagenase (Xiaflex®) on Dupuytren's disease fibroblasts displays unique drug related propertiesPloS One7e3143022384021|
|Vincent AS,Phan TT,Mukhopadhyay A,et al. Year: 2007Human skin keloid fibroblasts display bioenergetics of cancer cellsJ Invest Dermatol12870270917943178|
|Willems L,Chapuis N,Puissant A,et al. Year: 2012The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemiaLeukemia261195120222143671|
|Xing JZ,Zhu L,Jackson JA,et al. Year: 2005Dynamic monitoring of cytotoxicity on microelectronic sensorsChem Res Toxicol1815416115720119|
|Xue Q,Hopkins B,Perruzzi C,et al. Year: 2008Palomid 529, a novel small-molecule drug, is a TORC1/TORC2 inhibitor that reduces tumor growth, tumor angiogenesis, and vascular permeabilityCancer Res68955119010932|
|Yu K,Shi C,Toral-Barza L,et al. Year: 2010Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2Cancer Res7062120068177|
|Zhang Q,Kelly AP,Wang L,et al. Year: 2006Green tea extract and (−)-epigallocatechin-3-gallate inhibit mast cell-stimulated type I collagen expression in keloid fibroblasts via blocking PI-3K/Akt signaling pathwaysJ Invest Dermatol1262607261316841034|
Previous Document: T-cell reconstitution after thymus xenotransplantation induces hair depigmentation and loss.
Next Document: Tropomyosin Regulates Cell Migration during Skin Wound Healing.